The reporting of osteonecrosis of the jaw (ONJ) related to anticancer agents without known antiresorptive properties (non-antiresorptives), such as antiangiogenics, tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors, immune checkpoint inhibitors, and cytotoxic chemotherapy is increasing.
Nicolatou-Galitis, O., Kouri, M., Papadopoulou, E., Vardas, E., Galiti, D., Epstein, J.B., et al. (2018). Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. SUPPORTIVE CARE IN CANCER [10.1007/s00520-018-4501-x].
Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review
Campisi, Giuseppina;
2018-01-01
Abstract
The reporting of osteonecrosis of the jaw (ONJ) related to anticancer agents without known antiresorptive properties (non-antiresorptives), such as antiangiogenics, tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors, immune checkpoint inhibitors, and cytotoxic chemotherapy is increasing.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Nicolatou-Galitis2018_Article_OsteonecrosisOfTheJawRelatedTo.pdf
Solo gestori archvio
Tipologia:
Versione Editoriale
Dimensione
1.63 MB
Formato
Adobe PDF
|
1.63 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
